Surveillance Intervals After Piecemeal Resection of Non-pedunculated Colorectal Lesions ≥20mm

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorAsociación Española de Gastroenterología

About this trial

Intensive endoscopic surveillance following piecemeal resection of non-pedunculated colorectal lesions (NPCL) ≥20 mm is the current standard of care, given the high recurrence rate of these lesions (15-30%). However, most recurrences are detected at 12 months, are small and unifocal, and can be easily resected endoscopically. Furthermore, thermal margin ablation has demonstrated a reduction in recurrence rates to 5-6%, highlighting the need to optimize current surveillance protocols, which are costly, invasive, and impose a significant clinical burden.

The multicenter SCARFACE clinical trial aims to evaluate whether a reduced surveillance protocol (at 12 and 48 months) is non-inferior to the standard protocol (at 6, 12, and 48 months) in terms of recurrence rates, using a predefined non-inferiority margin. This non-inferiority design aims to determine if the reduced protocol maintains acceptable efficacy while reducing clinical workload and minimizing risks and discomfort associated with intensive follow-up.

Patients will be randomized in a 1:1 ratio into the two surveillance protocols, with an estimated sample size of 746 lesions. The primary objective is to compare the cumulative incidence of recurrence at 12 months. Secondary objectives include characterizing recurrences, assessing complications associated with endoscopic treatments and evaluating the incidence of advanced colorectal lesions. The findings of this study are expected to directly impact clinical guidelines and routine practice, optimizing resource utilization and improving patient quality of life.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with a single non-pedunculated colorectal lesion (NPCL) ≥20 mm that has been resected piecemeal and treated with thermal ablation (using snare tip or argon plasma) at the margins as prophylaxis against recurrence, and who are awaiting the initiation of specific endoscopic follow-up.

Complete colonoscopy with adequate or excellent bowel preparation performed within the last 6 months prior to the resection of the index lesion.

Signed informed consent.

Disqualifiers

Resection performed using a cold snare technique due to the high risk of recurrence.

Histology of the lesion showing malignancy: colorectal cancer with submucosal invasion, regardless of invasion depth in microns.

Absence of information regarding the grade of dysplasia of the index lesion.

Personal history of colorectal cancer.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Colonoscopy

    Procedure/Surgery

    Surveillance colonoscopy

Treatment groups

746 Participants
are divided into 2 treatment groups
Group A: Reduced surveillance intervalExperimental treatment 1 intervention
Group B: Standard surveillance intervalPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Cumulative incidence of recurrence/residual tissue

Time frame
12 months

Secondary outcomes

1

To compare the cumulative incidence of recurrence/residual tissue

Time frame
48 months
2

To describe the characteristics of recurrences

Time frame
48 months
3

To determine the complete endoscopic resection rate in patients who have experienced recurrence.

Time frame
48 months
4

To analyze the incidence of complications arising from the endoscopic treatment of recurrences.

Time frame
48 months

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Asociación Española de Gastroenterología

Lead sponsor

Instituto de Investigación Sanitaria y Biomédica de Alicante

Collaborator

This trial is not recruiting at the moment. You can still explore other options: